慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素

doi:10.6040/j.issn.1671-7554.0.2016.1063

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (7): 73-78.doi: 10.6040/j.issn.1671-7554.0.2016.1063

慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素

刘秋霞¹,王磊¹,刘峰¹,曲云东¹,叶茜¹,钱钰¹,张媛²,张立新¹

山东大学第二医院 1.肝病科;2.循证医学中心, 山东济南 250033

收稿日期:2016-08-26 出版日期:2017-07-10 发布日期:2017-07-10
通讯作者: 王磊. E-mail:wlcrb@sdu.edu.cn E-mail:wlcrb@sdu.edu.cn
基金资助:
艾滋病和病毒性肝炎等重大传染病防治和“十二五”国家科技重大专项“山东省乙型病毒性肝炎防治综合示范区规模化现场流行病学和干预研究”项目(2013ZX10004902);山东省医药卫生科技发展计划项目(2014WS0424)

Hypophosphatemia during long-term adefovir dipivoxil therapy in patients with hepatitis B virus infection

LIU Qiuxia¹, WANG Lei¹, LIU Feng¹, QU Yundong¹, YE Qian¹, QIAN Yu¹, ZHANG Yuan², ZHANG Lixin¹

1. Department of Hepatology;
2. Center of Evidence-based Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China

Received:2016-08-26 Online:2017-07-10 Published:2017-07-10

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎病毒(HBV)感染患者中阿德福韦酯(ADV)相关肾性低磷血症的发生率及影响因素。方法回顾性分析自2005年6月至2015年6月在山东大学第二医院开始接受ADV或ADV联合拉米夫定(LAM)抗病毒治疗并随诊1年以上的慢性HBV感染患者的临床资料。评估血清磷酸盐水平、血清肌酐和估计肾小球滤过率(eGFR),采用Kaplan Meier方法计算低磷血症的累积发生率。结果 243例慢性HBV感染患者中,慢性乙型肝炎(慢乙肝)和乙型肝炎肝硬化(乙肝肝硬化)分别是171例和72例,服用ADV的中位数时间为66(12~120)个月,有24例患者发生低磷血症。在2~10年时慢乙肝和乙肝肝硬化的低磷血症累计发生率分别为:0.6%、0.6%、0.6%、3.2%、6.2%、11.2%、14.2%、14.2%、19.9%和1.5%、3.3%、7.9%、10.4%、13.7%、23.9%、32.3%、49.3%、49.3%(χ2=6.685, P=0.010)。Cox多因素分析提示,ADV联合LAM(HR=2.661, P=0.010)、乙肝肝硬化(HR=2.886, P=0.020)是低磷血症发生的独立危险因素。结论慢性HBV感染患者长期服用ADV可引起低磷血症。LAM联合ADV以及肝硬化患者更易发生。

关键词: 慢性乙型肝炎, 低磷血症, 阿德福韦酯

Abstract: Objective To assess the cumulative incidence of hypophosphatemia caused by long-term treatment with adefovir dipivoxil(ADV)in patients with hepatitis B virus(HBV)infection and to explore the risk factors. Methods The patients who received ADV monotherapy or ADV plus lamivudine(LAM)for more than 1 year were recruited. Serum phosphate level, serum creatinine and estimated glomerular filtration rate(eGFR)were evaluated. Cumulative incidences of hypophosphatemia were calculated with Kaplan-Meier method. Results Of the 243 cases involved, 171 were chronic hepatitis B(CHB)and 72 were liver cirrhosis(LC). During a median treatment duration of 66(12-120)months, 24 patients developed hypophosphatemia. The cumulative incidences of hypophosphatemia for CHB and LC cases during 2-10 years were 0.6%, 0.6%, 0.6%, 3.2%, 6.2%, 11.2%, 14.2%, 14.2%, 19.9%, and 1.5%, 3.3%, 7.9%, 10.4%, 13.7%, 23.9%, 32.3%, 49.3% and 49.3%, respectively(χ2=6.685, P=0.010). Multivariate analysis identified LC(HR=2.886, P=0.020)and ADV plus LAM(HR=2.661, P=0.010) 山东大学学报 (医学版)55卷7期 -刘秋霞,等.慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素 \=-as independent predictors of hypophosphatemia. Conclusion Long-term treatment of hepatitis B with ADV or ADV plus LAM can potentially cause hypophosphatemia. LC patients treated with ADV plus LAM are more likely to develop hypophosphatemia.

Key words: Adefovir dipivoxil, Hypophosphatemia, Chronic hepatitis B

中图分类号:

R512.6

刘秋霞,王磊,刘峰,曲云东,叶茜,钱钰,张媛,张立新. 慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素[J]. 山东大学学报（医学版）, 2017, 55(7): 73-78.

LIU Qiuxia, WANG Lei, LIU Feng, QU Yundong, YE Qian, QIAN Yu, ZHANG Yuan, ZHANG Lixin. Hypophosphatemia during long-term adefovir dipivoxil therapy in patients with hepatitis B virus infection[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 73-78.

参考文献

[1] 茅益民,曾民德. 抗乙型病毒性肝炎新药——阿德福韦酯[J]. 中华肝脏病杂志, 2004, 12(1): 61-63. MAO Yimin, ZENG Minde. Adefovir dipivoxil-A new drug for hepatitis B[J]. Chin J Hepatol, 2004, 12(1): 61-63.
[2] 冯铁柱, 岑枝梅. 核苷(酸)类似物治疗慢性乙型肝炎的不良反应荟萃[J]. 中华实验和临床感染病杂志(电子版), 2013, 7(1): 107-109.
[3] Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies[J]. Kidney Int, 2004, 66(3): 1153-1158.
[4] 曲云东, 叶茜, 王磊, 等. 39例阿德福韦酯相关肾性低磷血症及骨软化症临床分析和初步转归[J].中华传染病杂志, 2015, 33(11): 678-681. QU Yundong, YE Qian, WANG Lei, et al. Clinical features and individualized treatment of 39 cases of adefovir dipivoxil-induced renal hypophosphatemia and osteomalacia[J]. Chin J Infect Dis, 2015, 33(11): 678-681.
[5] 国家食品药品监管总局提示关注阿德福韦酯的低磷血症及骨软化风险[J]. 世界临床药物, 2014, 35(12): 731.(2014-12-10)[2012-12-10] http://www.sfda.gov.cn/WS01/CL0051/110621.html.
[6] Girgis CM, Wong T, Ngu MC, et al. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil[J]. J Clin Gastroenterol, 2011, 45(5): 468-473.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中华肝脏病杂志, 2011, 19(1): 13-24.
[8] Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. New Engl J Med, 2012, 367(1): 20-29.
[9] 邹羽真, 胡扬, 张波. 阿德福韦酯致范可尼综合征1例及41例不良反应报道汇总分析[J]. 临床药物治疗杂志, 2015, 13(2): 68-73. ZOU Yuzhen, HU Yang, ZHANG Bo. Fanconis Syndrome induced by adefovir: A case report and pooled analysis of 41 cases[J].Clinical Medication Journal, 2015, 13(2): 68-73.
[10] Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial[J]. JAMA, 1999, 282(24): 2305-2312.
[11] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[J]. N Eng J Med, 2003, 348(9): 800-807.
[12] Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. N Eng J Med, 2003, 348(9): 808-816.
[13] 何顺梅, 张尧, 吕朝阳, 等. 阿德福韦酯致Fanconi综合征并继发低磷性骨软化症4例[J]. 复旦学报(医学版), 2014, 41(3): 374-379. HE Shunmei, ZHANG Yao, LV Chaoyang, et al. Hypophosphataemic osteomalacia in the context of Fanconis syndrome secondary to adefovir theraphy: 4 cases report and literature review[J]. Fudan Univ J Med Sci, 2014, 41(3): 374-379.
[14] 李玲, 董光富, 张晓, 等. 阿德福韦酯致Fanconi综合征和低磷性骨软化症并进行性肌无力1例[J]. 南方医科大学学报, 2011, 31(11): 1956. LI Ling, DONG Guangfu, ZHANG Xiao, et al. Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B[J]. J South Med Univ, 2011, 31(11): 1956.
[15] Tanaka M, Suzuki F, Seko Y, et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J]. J Gastroenterol, 2013, 49(3): 470-480.
[16] 宁会彬, 李宽, 李威, 等. 阿德福韦酯对慢性乙型肝炎患者血磷代谢的影响及其相关因素分析[J]. 中华肝脏病杂志, 2015, 23(8): 590-593. NING Huibin, LI Kuan, LI Wei, et al. Adefovir dipivoxil effects on and related factors of blood phospaotus metabolism in patients with chronic hepatitis B[J]. Chin J Hepatol, 2015, 23(8): 590-593.
[17] 刘玉柱, 闵祥玺. 阿德福韦酯对慢性乙型肝炎患者血磷和骨密度的影响[J]. 肝脏, 2016, 21(5): 341-343. LIU Yuzhu, MIN Xiangxi. Effects of adefovir dipivoxil on serum phosphate level and bone mineral density in patients with chronic hepatitis B[J]. Chinese Hepatology, 2016, 21(5): 341-343.
[18] 苏淼, 赵彩彦, 赵欣, 等. 慢性乙型病毒性肝炎患者在阿德福韦酯治疗期间血磷浓度和骨密度的变化[J]. 中华内科杂志, 2015, 54(4): 332-333.
[19] 田敬华, 何艳群, 马小艳, 等. 慢性乙型肝炎患者在阿德福韦酯治疗期间的肌酐和血磷水平变化[J]. 中华肝脏病杂志, 2013, 21(3): 239-240. TIAN Jinghua, HE Yanqun, MA Xiaoyan, et al. The observation of blood serum creatinine and phosphorus during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J]. Chin J Hepatol, 2013, 21(3): 239-240.
[20] Qi X, Wang J, Chen L, et al. Impact of nucleos(t)ide analogue combination thepapy on the eatimated glomerular filtration rate in patients with chronic hepatitis B[J]. Medicine, 2015, 94(15): e646.
[21] 赵康路, 郭秋芳, 叶卫江. 单用或联合使用阿德福韦酯引起尿β2-微球蛋白改变的研究[J]. 浙江临床医学, 2016, 18(2): 253-255.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素

Hypophosphatemia during long-term adefovir dipivoxil therapy in patients with hepatitis B virus infection

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

多维度评价

本文评价

推荐阅读 0

[1]	张琨,张孝国,崔杏杏,陈士俊. 慢性HBV感染者外周血单个核细胞凋亡相关因子的表达及其与乙肝慢性化的关系[J]. 山东大学学报（医学版）, 2016, 54(7): 38-42.
[2]	钱钰,曲云东,王子瑜,刘峰,叶茜,王磊. 影响慢性乙型肝炎病毒感染患者肾功能的危险因素[J]. 山东大学学报（医学版）, 2016, 54(1): 29-32.
[3]	欧珠美朵, 嘎松卓嘎, 旦增. 白细胞介素-10基因多态性与西藏地区慢性乙型肝炎的相关性研究[J]. 山东大学学报（医学版）, 2014, 52(S1): 9-9.
[4]	刘同燕1,张龙跃2,李月荣3,孙经利2,韩增禄3,李志荃2,张立新1,王磊1. 干扰素α与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎前瞻性队列观察[J]. 山东大学学报（医学版）, 2014, 52(6): 72-78.
[5]	潘家超1,2，张乐1,2，徐琳琳3，单晓宇2，杜文军2，陈士俊2. 黑素瘤缺乏因子2诱导的固有免疫在慢性乙型肝炎发病机制中的作用[J]. 山东大学学报（医学版）, 2014, 52(4): 74-79.
[6]	刘伟1，丁艾昆2，李程2，单容3，王昌源1,2. 慢性乙型肝炎疾病进展中瞬时弹性波检测的意义及其影响因素[J]. 山东大学学报（医学版）, 2014, 52(1): 85-88.
[7]	符晓莉，王磊，刘峰. 乙肝病毒感染不同阶段血清HBsAg定量值及其与HBV DNA水平和年龄的相关性[J]. 山东大学学报(医学版), 2013, 51(5): 94-98.
[8]	张秀珍,刘莉,刘倩. 慢性乙型肝炎患者血清瘦素水平与抗病毒治疗应答的相关性[J]. 山东大学学报(医学版), 2012, 50(9): 96-99.
[9]	刘峰,王磊,王丽娜,耿大影. 阿德福韦酯治疗慢性乙型肝炎过程中发生病毒突破患者的（HBV）P基因变异分析[J]. 山东大学学报(医学版), 2008, 46(4): 407-410.